-
Advantages of Small Molecule Inhibitors in Therapeutic Interventions(Post)
Small molecule inhibitors represent a significant advancement in the field of therapeutic interventions, offering a versatile approach to treating a myriad of diseases, including cancer, viral in ...
Personalized Vaccines in Cancer Treatment: The Future of Immunotherapy(Post)What Are Personalized Cancer Vaccines? Personalized cancer vaccines are a cutting-edge approach in cancer treatment that are designed to activate a patient's immune s ...
Obinutuzumab: Advancing Targeted Therapy in Hematologic Cancers(Post)Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leuke ...
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly expres ...
Targeting Immune Checkpoints as Cancer Therapy(Post)In recent years, the field of oncology has witnessed a paradigm shift with the advent of immunotherapy, a treatment modality that harnesses the body's immune system to combat cancer. Among the mo ...
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma ...
Tocilizumab: Advancing Therapeutics and Research with Biosimilars(Post)What You Need to Know About TocilizumabWhat is Tocilizumab?Tocilizumab is a monoclonal antibody that targets the interleukin-6 (IL-6) receptor, widely used for managing autoimmune and i ...
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including no ...
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized ...
Macrophage Activation: A Keystone in Immune Response and Therapeutic Potential(Post)In the intricate tapestry of the immune system, macrophages play a pivotal role, orchestrating a wide range of biological responses that protect the body against pathogens, remove cellular debris ...
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By ...
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors ...
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics(Post)Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the m ...
Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Do ...
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-li ...
Cancer Metabolism: Tumorigenesis, Metabolic Therapy & The Warburg Effect(Post)Cancer Metabolism is the mechanism by which cancer cells make energy in order for them to grow and spread. Even in the presence of oxygen, cancer cells increase glucose uptake and produce lactate ...
Pamrevlumab: Unveiling the Potential of Anti-Fibrotic Therapy in Clinical Trials and Research(Post)Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver o ...
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking ...
STING Activators As Cancer Therapeutics(Post)The STING (Stimulator of Interferon Genes) pathway plays a pivotal role in the innate immune system's response to cancerous cells and DNA viruses. Exploiting this pathway through STING activators ...
Ozuriftamab: A Closer Look at This Anti-CD47 Antibody in Cancer Immunotherapy(Post)What You Need to Know About OzuriftamabWhat is Ozuriftamab?Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer ...
VEGF-A VEGFR-2 Signaling: Decoding the Blueprint of Angiogenesis for Therapeutic Insights(Post)The orchestration of angiogenesis, the process by which new blood vessels form from pre-existing ones, is a complex symphony regulated by various molecular players. At the forefront of this in ...
Exploring the Frontier of Immunotherapy: T Cell Expansion(Post)In the realm of immunotherapy, T cell expansion has emerged as a pivotal strategy, holding promise in the treatment of various diseases, particularly cancer. T cells are a critical component o ...
Understanding T Cell Fatigue: Implications for Immune Function and Therapeutic Interventions(Post)T cells are central players in adaptive immunity, responsible for recognizing and eliminating infected or aberrant cells. Upon encountering antigens, T cells undergo clonal expansion and diffe ...
Trastuzumab: Revolutionizing HER2-Positive Cancer Treatment & Research(Post)Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, r ...
CAR-NK Cell Therapy: The Next Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a relentless battle of incremental gains. While immunotherapies like CAR-T cell therapy have offered revolutionary hope, their personalized nature, hig ...
Anti-CTLA-4 Immunotherapy(Post)CD Markers Cluster of Differentiation (CD) markers play an important role in the differentiation of B cells, T cells and NK (natural killer) c ...
Galectin Therapeutics(Post)Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a chronic, irreversible and ultimately fatal disease characterized by pro ...
The PD-1 Pathway and Cancer Immunotherapy(Post)The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses ...
Immunometabolism – A therapeutic perspective(Post)What is Immunometabolism? Immunometabolism is an exponentially growing, multi-disciplinary field of research aiming at deciphering the dynamic cellular and mol ...
TLX as a Novel Therapeutic Target(Post)Danka Kozareva PhD Candidate, University College Cork The generation of neurons from stem cells The process of generating ...
Promising COVID-19 Therapeutics(Post)SARS-CoV-2, the causative viral agent of the novel coronavirus disease COVID-19, has sparked a global effort for creating prophylactic and therapeutic interventions. The following ...
What is CAR T-cell therapy?(Post)CAR T-cell therapy CAR (Chimeric Antigen Receptor) T-cell Therapy is a type of cancer treatment. CAR T-cells are made in the laboratory and they have an artificially created receptor on th ...
Ferroptosis: A New Frontier in Cancer Therapy(Post)For decades, the primary strategy in cancer treatment has been to trigger apoptosis, a form of programmed cell death, in malignant cells. However, many cancers develop resistance to apoptosis-induci ...
CTLA-4 in Breast Cancer: Insights for Immunotherapy(Post)The Role of CTLA-4 in Breast Cancer: Implications for ImmunotherapyBreast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, with significant morbidity and mortalit ...
Platelets : The Unassuming Heroes of Blood Circulation(Post)Platelets, the tiny cellular fragments found in our blood, play a crucial role in maintaining our overall health and well-being. From their role in blood clotting to their involveme ...
PD-L1 in Cancer Immunotherapy: Key Insights(Post)PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune eva ...
Pyroptosis: A Promising Target for Immunotherapy(Post)Pyroptosis is an immunogenic form of cell death, meaning that it triggers an immune response. This makes pyroptosis a potentially promising target for immunotherapies that aim to bo ...
Biomarkers & Inflammatory markers of atherosclerosis(Post)As atherosclerosis is a complex inflammatory disease, there are many influential biomarkers that contribute to the disease’s progression as well as biomarkers from atherosclerosis related d ...
Adhesion molecules in atherosclerosis – ICAM1(Post)Adhesion Molecules Direct cell-cell interactions are maintained and regulated by cell adhesion molecules. The expression of adhesion molecule ...
Understanding the Bcl-2 Pathway in Cancer Therapy(Post)Understanding the Bcl-2 Pathway: Implications for Cancer Therapy The Bcl-2 family of proteins plays a pivotal role in regulating apoptosis, a crucial process for maintaining cellula ...
B7-H3: A Promising New Target in Tumor Immunotherapy(Post)B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role ...
Targeting Immune Checkpoints as Cancer Therapy(Post)The advent of immune checkpoint targeting marks a significant milestone in the oncological field, offering a beacon of hope for patients battling cancer. This innovative approach leverages the bo ...
Novel Gene Therapy for Cystic Fibrosis (Post)Novel Gene Therapies for Cystic Fibrosis Cystic Fibrosis Cystic fibrosis (CF) is an autosomal recessive, life-limiting disease resulting from gene mutations that encode the cystic fib ...
miRNAs as therapeutics and biomarkers for pancreatic cancer(Post)Pancreatic cancer survival rates Despite recent advances in our understanding of this disease, pancreatic cancer is one of the world’s most lethal maligna ...
Dupilumab: Transforming Immunotherapy and Skin Disease Management(Post)What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines ...
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin ly ...
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mec ...
LILT: A Novel Immune Checkpoint for Cancer Therapy(Post)Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this g ...
The double-edged sword in prostate cancer therapy(Post)By Zoe Angel, PhD Student, Ulster University Prostate cancer is now the commonest cancer in men and it is the fifth leading cause of death (1). Researc ...
Ivuxolimab: Redefining Cancer Immunotherapy and Research(Post)Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does ...
Tarextumab: Unlocking the Potential of Cancer Therapeutics(Post)Quick Facts About TarextumabWhat is Tarextumab?Tarextumab is a novel therapeutic antibody designed to target the Notch signaling pathway, which plays a crucial role in tumor progression ...
CD86: Enhancing T Cell Activation in Immunotherapy(Post)Introduction to CD86 and Its Role in Immune Activation CD86 is a crucial co-stimulatory molecule that plays an essential role in T cell activation, driving the immune system’s abili ...
Myeloid Cell Networks in Cancer Immunotherapy(Post)Understanding Myeloid Cell Networks in Cancer ImmunotherapyImmunotherapy has revolutionized cancer treatment, yet its effectiveness in re-establishing original immune responses post-therapy remains l ...
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer ...
Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab w ...
HERV-K group of endogenous retroviruses and cancer(Post)In 2006, upon completion of the Human Genome Project, it was discovered that nearly 8% of the human genome is made up of viral DNA. These viral remnants are composed of ancient germ ...
Glenzocimab: A Novel Antiplatelet Therapy for Stroke Prevention(Post)Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycop ...
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved fo ...
Enapotamab: Advancing Cancer Research with Innovative Therapeutics(Post)Quick Facts About EnapotamabWhat is Enapotamab?Enapotamab is an experimental antibody-drug conjugate (ADC) developed to target tumor cells selectively, offering new hope in cancer treat ...
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmu ...
Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy(Post)Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under inves ...
Phosphorothioate: Enhancing Stability in Oligonucleotide-Based Therapies(Post)Phosphorothioate is a chemical modification commonly used in oligonucleotide-based therapies to enhance the stability and efficacy of therapeutic nucleic acids. In this modification, one ...
Cystic Fibrosis: Causes, Inheritance, Treatment and Diagnosis(Post)What is Cystic Fibrosis? Cystic fibrosis (CF) is a genetic disorder that impairs the body's ability to produce sweat and thick mucus. CF causes mucus to build up in ...
Xeroderma pigmentosum: Causes, Inheritance, Treatment and Diagnosis(Post)What is Xeroderma Pigmentosum? Xeroderma pigmentosum (XP) also known De Sanctis-Cacchione syndrome is a rare genetic disorder that affects the skin, eyes and central nervous system. It is c ...
Antigen Presenting Cells (APCs) and cancer immunotherapy(Post)Explore antigen presentation's crucial role in adaptive immunity and its impact on cancer immunotherapy, highlighting the diversity and function of MHC class I molecules. Key Takeawa ...
Exosomes: Tiny Messengers Revolutionizing Cancer Diagnosis and Therapy(Post)In the intricate world of cancer biology, a silent conversation is constantly unfolding between tumor cells and their environment. For decades, we viewed this dialogue as a one-way street, with cance ...
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine t ...
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies(Post)1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive ...
Anti-CTLA-4: Unleashing the Power of T Cells in Combination Immunotherapy(Post)Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to fight malignancies. Among the notable advancements in this field is the development of immune ...
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macroph ...
Dual PD-1/PD-L2 Blockade: Expanding the Horizons of Cancer Immunotherapy(Post)Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhib ...
In Vivo CAR-T Engineering: The Dawn of Off-the-Shelf Immunotherapy(Post)Imagine a future where cancer treatment isn't a grueling, months-long process involving cell extraction and reinfusion, but a simple, targeted injection that reprograms your body's own immune cells ...
Apamistamab: Advancing Leukemia Treatment through Targeted Radioimmunotherapy(Post)Quick Facts About ApamistamabWhat is Apamistamab?Apamistamab is a monoclonal antibody that targets the CD45 antigen on hematopoietic cells.How does Apamistamab work?When labeled with th ...
Platinum based cancer drugs and next generation therapeutics(Post)Platinum based cancer drugs Despite nearly 50% of all anti-cancer treatments being platinum-based, there is an urgent need to develop novel therapeutics ...
Reprogramming Regulatory T Cells: A Breakthrough in Cancer Immunotherapy(Post)A New Dawn in Cancer Treatment: Reprogramming the Immune System's Own Soldiers For decades, the fight against cancer has been a relentless battle of attrition, with treatments like chemotherapy and ...
Polatuzumab: Redefining Targeted Therapies in B-Cell Lymphoma(Post)What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-ce ...
Anifrolumab: Transforming Lupus Treatment with Targeted Immunotherapy(Post)Quick Facts About AnifrolumabWhat is Anifrolumab?Anifrolumab is a monoclonal antibody that targets the type I interferon receptor, playing a crucial role in treating systemic lupus eryt ...
Tinurilimab: Advancing Immunotherapy Through CD47 Blockade(Post)Quick Facts About TinurilimabWhat is Tinurilimab?Tinurilimab is a monoclonal antibody targeting CD47, a protein that cancer cells use to evade immune system attack. By blocking CD47, Ti ...
Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements(Post)Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the ...
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating ...
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How d ...
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune sys ...
CD122: Fine-Tuning T Cell Responses in Immunotherapy(Post)Introduction to CD122 in Immunotherapy CD122, also known as the interleukin-2 receptor beta chain (IL-2Rβ), is a critical component of the immune system's response to pathogens and ...
LAG-3: Revitalizing T Cells in Exhaustion for Combination Therapies(Post)Lymphocyte Activation Gene-3 (LAG-3) is an immune checkpoint receptor that plays a critical role in regulating T cell function. In recent years, LAG-3 has emerged as a potential target f ...
Anti-PD-1: Restoring T Cell Function in Cancer Immunotherapy(Post)Cancer immunotherapy has revolutionized the treatment landscape for various malignancies. One of the most promising therapeutic strategies is the use of immune checkpoint inhibitors, par ...
Protein Kinases: Overview, Classification and Therapeutic Potential(Post)Kinases, key enzymes in cellular signaling, phosphorylate proteins to regulate crucial processes, and their modulation has significant implications in disease treatment. Key Takeaways: K ...
Extracellular Vesicles in Neurodegenerative Disease: From Pathology to Therapeutic Potential(Post)In the intricate landscape of the brain, cells constantly communicate, sending and receiving messages that govern our thoughts, memories, and movements. For decades, scientists believed this communic ...
A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics(Post)A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disease that has long puzzled researchers and clinicians. Howev ...
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune de ...
Narsoplimab: Targeting MASP-2 to Advance Therapies in Immune-Mediated Disorders(Post)Quick Facts About NarsoplimabWhat is Narsoplimab?Narsoplimab is a human monoclonal antibody that targets MASP-2, a key enzyme in the lectin pathway of the complement system.What is the ...
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune des ...
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detec ...
TREM2: Exploring Its Role in Tumor-Associated Macrophages and Cancer Immunotherapy(Post)Introduction to TREM2 and Tumor-Associated Macrophages in CancerTREM2 (triggering receptor expressed on myeloid cells 2) is an immunoregulatory receptor primarily expressed on macrophage ...
NK Cells: Unlocking the Potential of Natural Killer Cells in Cancer Therapy(Post)Natural killer (NK) cells are a crucial component of the innate immune system and play a significant role in eliminating tumor cells. Unlike T cells, NK cells can recognize and kill canc ...
Rescuing Exhausted T Cells: A New Frontier in Cancer Immunotherapy(Post)For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided wea ...
Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword(Post)Cellular Senescence in Cancer Immunotherapy: The Double-Edged Sword In the intricate world of cancer biology, some of our body's most potent defense mechanisms can paradoxically turn against us. Cel ...
Top 10 Therapeutics(Page)window.SHOGUN_IMAGE_ELEMENTS = window.SHOGUN_IMAGE_ELEMENTS || new Array(); window.SHOGUN_IMAGE_ELEMENTS.push({ hoverImage: '', uuid: 's-6ebebd0d- ...
Quick Test Strips & Other Reagents(Page)window.SHOGUN_IMAGE_ELEMENTS = window.SHOGUN_IMAGE_ELEMENTS || new Array(); window.SHOGUN_IMAGE_ELEMENTS.push({ hoverImage: '', uuid: 's-a2c94a79-131 ...
Therapeutic Antibody & Biosimilar ELISA Kits(Page)document.addEventListener("DOMContentLoaded",(function(){var e=document.querySelector(".page-sidebar");e&&e.remove(),document.querySelectorAll(".page-heading").forEach((function(e){e.re ...